Fig. 1

AGR2 correlated with doxorubicin-resistance in breast cancer cells. a-b Total RNA and protein were extracted from MDA-MB-231, MCF-7 and MCF-7/DOXR cells. a qPCR and b western blot were applied to analyze mRNA and protein levels of AGR2. c Cells were treated with gradient doses of doxorubicin for 48 h. MDA-MB-231: 1, 10, 30, 50, 100, 200, 400 nM; MCF-7: 10, 50, 100, 150, 200, 400, 800 nM; MCF-7/DOXR: 0.01, 0.1, 0.5, 1.0, 5.0, 20, 50 μM. Cell viability was measured by CCK-8 assay (n = 6). Viability of untreated cells was set as 100%. Experiment was repeated twice. Expression levels of mRNA represent fold changes. Data are shown as mean ± SD, compared using one-way ANOVA test. *, p < 0.05; MCF-7/DOXR, doxorubicin-resistant MCF-7 cells